Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

The Ad26.COV2.S vaccine(1–3) has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies(1). However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Alter, Galit, Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, Borducchi, Erica N., Tostanoski, Lisa H., McMahan, Katherine, Jacob-Dolan, Catherine, Martinez, David R., Chang, Aiquan, Anioke, Tochi, Lifton, Michelle, Nkolola, Joseph, Stephenson, Kathryn E., Atyeo, Caroline, Shin, Sally, Fields, Paul, Kaplan, Ian, Robins, Harlan, Amanat, Fatima, Krammer, Florian, Baric, Ralph S., Le Gars, Mathieu, Sadoff, Jerald, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357629/
https://www.ncbi.nlm.nih.gov/pubmed/34107529
http://dx.doi.org/10.1038/s41586-021-03681-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357629/
https://www.ncbi.nlm.nih.gov/pubmed/34107529
http://dx.doi.org/10.1038/s41586-021-03681-2

Ejemplares similares